News
This Simple Step Can Make Diabetes Patients Healthier -- and Possibly Wealthier
If you're one of the millions of Americans diagnosed with diabetes, large pharmacy benefits manager (PBM) Express Scripts (NASDAQ: ESRX) has good news for you. There's something you can do that....
Why Juno Therapeutics Stock Is Blasting Off Today
Shares of Juno Therapeutics (NASDAQ: JUNO) are up by double digits for the second day in a row on extremely heavy volume. The catalyst behind this continued surge higher is the nearly $12 billion....
Why Catalent Inc. Rose as Much as 17% This Morning
Shares of drug-delivery technology specialist Catalent (NYSE: CTLT) jumped as much as 17% Tuesday morning in the wake of the company's 2017 fiscal year earnings report, released Monday after the....
3 Healthcare Stocks to Buy With Dividends Yielding More Than 3%
There are fewer healthcare stocks with high yields than you might think. At least that's the case depending on your definition of "healthcare stocks" and "high yields." If you think a high-yield....
Get Ready for More Acquisitions by Gilead Sciences
Investors woke up Monday morning to a pleasant surprise from Gilead Sciences (NASDAQ: GILD). The big biotech announced plans to acquire Kite Pharma (NASDAQ: KITE) for $11.9 billion. The market....
Why Thor Industries, IXYS Corporation, and Kite Pharma Jumped Today
Activity on the stock market was muted today as investors focused on the damage left by Hurricane Harvey. The major benchmarks showed mixed results, but stayed close to where they started the day.....
Why bluebird bio Inc and Juno Therapeutics Inc Shot Higher Today
bluebird bio (NASDAQ: BLUE) is up 9.5% and Juno Therapeutics (NASDAQ: JUNO) is up 17% at 12:40 p.m. EDT Monday. Both appear to be riding the coattails of fellow immuno-oncology drug developer Kite....
Gilead's Plan? Cash In on CAR-T
Investors eagerly awaiting news of how Gilead Sciences' (NASDAQ: GILD) plans to spend its growing mountain of cash found out on Monday that the company's plans to become a leader in cancer....
Gilead Sciences to Buy Kite Pharma for $11.9 Billion: Is It Enough to Move the Needle?
Gilead Sciences (NASDAQ: GILD), prompted by its falling sales of its hepatitis C drugs over the past year, has finally pulled the trigger on a much-anticipated buyout: On Monday, it offered to....
In Your 60s? 3 Stocks You Might Want to Buy
For many Americans, reaching their 60s is often the point where they transition out of the labor force and into retirement. It means putting that alarm clock to bed for good and putting your feet....
Can Buying Exelixis Stock Still Make You Rich?
What were you doing on Friday, Jan. 2, 2015? It's OK if you don't remember. I certainly can't.But there were some investors who did something on that date who probably recall it with a smile.....
Why I Love AbbVie Inc.
"Where your treasure is, there will your heart be also."Those profound words were spoken nearly 2,000 years ago. They were true then, and they're still true today. But even when your treasure is....
Here Are the Big Pharma Stocks to Own Based on R&D Spending
Just because a big pharma company is successful today doesn't mean it will be successful in a few years. Even the biggest blockbuster drugs eventually lose patent exclusivity or face new and....
Is the System Rigged Against Biosimilars?
If you think prescription drug costs are high now, imagine what costs would be without generic drugs. Roughly 25% of total prescription drug sales in 2016 were generics. But it's a different story....
70 or Older? 3 Stocks You Should Consider Buying
Investment priorities naturally evolve as we age. For investors in their 70s, stability and income should be prioritized over growth and capital appreciation potential. That's why companies like....
4 of the Highest-Growth Stocks in Biotech Today
Investing in the biotech industry can be a risky business. In most instances, the deck is stacked against a company succeeding. The vast majority of preclinical studies will fail to reach human....
3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences
Gilead Sciences (NASDAQ: GILD) claims one of the top-selling drugs in the world with Harvoni. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. Gilead Sciences is one....
How Johnson & Johnson Makes Most of Its Money
As you might expect, Johnson & Johnson (NYSE: JNJ) makes a lot of money. Last year, the healthcare giant generated revenue totaling nearly $72 billion. Over the past decade, J&J raked in....
What's Next for Bristol-Myers Squibb After Its Opdivo Setback?
The signs were definitely there for a disappointment from Bristol-Myers Squibb (NYSE: BMY). Several weeks ago, AstraZeneca (NYSE: AZN) reported its checkpoint inhibitor Imfinzi failed to improve....
What's the Most Important Drug in Regeneron Pharmaceuticals' Pipeline?
Regeneron Pharmaceuticals (NASDAQ: REGN) has four significant medications on the market, including three that have won Food and Drug Administration approval since 2015, and it's investing big....
What Will Drive Regeneron Pharmaceuticals' Growth Higher From Here?
Regeneron Pharmaceuticals' (NASDAQ: REGN) $5 billion in sales in 2016 were due mostly to sales of its top-selling vision-restoring drug Eylea. However, a slate of newly Food and Drug....
Why Eylea Is Still Regeneron Pharmaceuticals' Most Important Drug
Aging baby boomers are turning 65 years old at a pace of 10,000 per day, and that's causing an increase in the diagnosis of common causes of vision loss, including age-related macular degeneration....
3 Top Stocks Under $5
Tiny stocks don't get a lot of love on Wall Street -- and by tiny I mean companies that have a share price of under $5. According to the Securities and Exchange Commission, any stock that trades....
3 Most Promising Cancer Drugs in Late-Stage Development
Progress marches on in the fight against cancer. While more biosimilars are becoming available for top cancer drugs of the past, biopharmaceutical companies are developing newer and more powerful....
3 High-Yield Pharmaceutical Stocks
The pharmaceutical industry is a natural hunting ground for reliable income stocks, since people buy drugs in good times and in bad. But which high-yield dividend stocks are actually worthy of....